Effectiveness of mRNA COVID-19 Monovalent and Bivalent Vaccine Booster Doses Against Omicron Severe Outcomes Among Adults Aged ≥50 Years in Ontario, Canada: A Canadian Immunization Research Network Study
Journal article published in 2023 by
Ramandip Grewal,
Sarah A. Buchan 
,
Lena Nguyen,
Sharifa Nasreen ,
Peter C. Austin,
Kevin A. Brown,
Jonathan Gubbay,
Nelson Lee,
Kevin L. Schwartz,
Mina Tadrous,
Kumanan Wilson,
Sarah E. Wilson,
Jeffrey C. Kwong
,
Lena Nguyen,
Sharifa Nasreen ,
Peter C. Austin,
Kevin A. Brown,
Jonathan Gubbay,
Nelson Lee,
Kevin L. Schwartz,
Mina Tadrous,
Kumanan Wilson,
Sarah E. Wilson,
Jeffrey C. Kwong
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
Abstract We estimated the effectiveness of booster doses of monovalent and bivalent mRNA COVID-19 vaccines against Omicron-associated severe outcomes among adults aged ≥50 years in Ontario, Canada. Monovalent and bivalent mRNA COVID-19 booster doses provided similar strong initial protection against severe outcomes. Uncertainty remains around waning of protection from these vaccines.